(Dec 11th, 2024) The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational Outcomes
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational
Dr Krista Rantanen has an extensive academic career in the field of cancer research, specifically focusing on oxygen sensing mechanisms. She did her PhD on prolyl hydroxylase function in cancer and subsequently she’s been a part of starting a biomedical engineering company and did her postdoctoral period studying kidney cancer.
In 2018 she joined the Baker Company (USA) as their Director of Scientific Applications and has pursued in this global role since. 2022 she was also invited to be a Visiting Scientist in the research group of Nobel Laureate Sir Peter Ratcliffe at the Francis Crick Institute in London UK. There she continues her research on oxygen sensing mechanisms.
Dr Rantanen is also the lead of the global science for science initiative HypoxEU, the society for oxygen biology research supporting the work of thousands of scientists in the field.
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational
(November 14, 2024) NIR-II Fluorescence imaging: Why, When and How Short-Wave Infrared (SWIR)
(November 13, 2024) Reduce and Prevent Contamination in Tissue and Cell Culture Laboratories
(October 2, 2024) Next Generation Bioprinting Platform: A Multimodal Approach for Bioprinting of
(September 18, 2024) Gamma Eye calibration, system characterization, and in vivo imaging of
(July 24, 2024) Webinar: Lab Incubator Decontamination: Why, When and How Laboratory incubators